Provided by Tiger Trade Technology Pte. Ltd.

Castle Biosciences, Inc.

29.57
-2.3100-7.25%
Post-market: 30.100.5300+1.79%18:09 EST
Volume:927.03K
Turnover:27.33M
Market Cap:863.11M
PE:-68.11
High:30.50
Open:29.87
Low:27.22
Close:31.88
52wk High:44.28
52wk Low:14.59
Shares:29.19M
Float Shares:26.72M
Volume Ratio:1.71
T/O Rate:3.47%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4342
EPS(LYR):0.6200
ROE:-5.21%
ROA:-4.82%
PB:1.83
PE(LYR):47.69

Loading ...

Assessing Castle Biosciences (CSTL) Valuation After New Uveal Melanoma Data and Renewed Analyst Optimism

Simply Wall St.
·
Dec 25, 2025

Castle Biosciences (CSTL) Is Up 6.5% After New Melanoma Data Validates DecisionDx Tests

Simply Wall St.
·
Dec 24, 2025

Castle Biosciences Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Dec 22, 2025

Castle Biosciences COO Kristen M. Oelschlager Reports Disposal of Common Shares

Reuters
·
Dec 20, 2025

BRIEF-Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Dec 19, 2025

Castle Biosciences Grants RSUs to 83 New Employees under Inducement Plan

Reuters
·
Dec 19, 2025

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Dec 19, 2025

Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares

Reuters
·
Dec 18, 2025

Castle Biosciences Study Finds DecisionDx-UM Plus PRAME Outperforms Gene Mutation Analysis in Uveal Melanoma Prognosis

Reuters
·
Dec 17, 2025

Should Expert Endorsement of DecisionDx-Melanoma’s Prognostic Value Require Action From Castle Biosciences (CSTL) Investors?

Simply Wall St.
·
Dec 16, 2025

Castle Biosciences CFO Frank Stokes Reports Disposal of Common Shares

Reuters
·
Dec 16, 2025

Castle Biosciences Inc : Btig Raises Target Price to $50 From $38

THOMSON REUTERS
·
Dec 12, 2025

Castle Biosciences Study Confirms TissueCypher Outperforms Traditional Methods in Predicting Esophageal Cancer Risk

Reuters
·
Dec 12, 2025

Systematic Review and Meta-Analysis Confirms Tissuecypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

THOMSON REUTERS
·
Dec 12, 2025

Castle Biosciences Is Maintained at Buy by BTIG

Dow Jones
·
Dec 12, 2025

Castle Biosciences’ DecisionDx-Melanoma Endorsed as Best-Practice Tool by Expert Panel

Reuters
·
Dec 09, 2025

Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares

Reuters
·
Dec 09, 2025

Castle Biosciences CEO Derek J. Maetzold Reports Sale of Common Shares

Reuters
·
Dec 02, 2025

Castle Biosciences CEO Derek J. Maetzold Reports Disposal of Common Shares

Reuters
·
Nov 27, 2025

Castle Biosciences Chief Commercial Officer Tobin W. Juvenal Reports Disposal of Common Shares

Reuters
·
Nov 25, 2025